New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 30, 2014
08:31 EDTXNPTXenoPort says ISS recommends investors vote for all director nominees
XenoPort announced that Institutional Shareholder Services has recommended that XenoPort stockholders vote “FOR ALL” of XenoPort’s director nominees on the WHITE proxy card at the company’s Annual Meeting of Stockholders to be held on June 11. In supporting XenoPort’s entire slate of director nominees, ISS recommends that stockholders “do not vote” for any of the three nominees proposed by Clinton Relational Opportunity Master Fund, L.P. and its affiliates. ISS also recommends XenoPort stockholders vote “FOR” the approval of XenoPort, Inc. 2014 Equity Incentive Plan, vote “FOR” the approval, on an advisory basis, the compensation of XenoPort’s named executive officers, and vote “FOR” the ratification of the selection by the audit committee of the board of directors of Ernst & Young LLP as XenoPort’s independent registered public accounting firm for the fiscal year ending December 31.
News For XNPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 11, 2015
15:05 EDTXNPTXenoPort believes FDA accepeted NIAAA design for Horizant trial
Subscribe for More Information
15:04 EDTXNPTXenoPort says Horizant 13-week prescriptions increased 18%
XenoPort reported an update on prescription trends and further development of Horizant Extended-Release Tablets, including feedback from the FDA on development for treatment of alcohol use disorder. Horizant prescription trend highlights include: The number of nation-wide prescribed tablets for the 13 weeks ending December 19, 2014 was 1,256,082, an increase of 18% compared to the prior 13 weeks ending September 19, 2014 and an increase of 95% over the 13-week period ending December 20, 2013. The rolling four-week average of prescribed tablets for the week ending December 19, 2014 was 100,742. The current wholesale acquisition cost price is $7.69 per tablet. During Q3, XenoPort increased its field sales force of NeuroHealth Sales Specialists from approximately 40 to 65 representatives. The number of prescribed tablets for the 13 weeks ending December 19, 2014 in the territories occupied by the new NHS Specialists was 227,897, an increase of 46% compared to the 13 weeks ending June 27, 2014, which was prior to the addition of the new NHS Specialists.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use